首页 > 最新文献

Journal of Clinical and Experimental Hematopathology最新文献

英文 中文
Extranodal natural killer/T-cell lymphoma coexisting with peripheral T-cell lymphoma, not otherwise specified. 结节外自然杀伤/T 细胞淋巴瘤与外周 T 细胞淋巴瘤并存,未作其他说明。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.23049
Kenta Hayashino, Chikamasa Yoshida, Yoshiyuki Ayata, Ryouya Yukawa, Aya Komura, Makoto Nakamura, Yusuke Meguri, Kazuhiko Yamamoto, Wakako Oda, Kenji Imajo

We report the case of a 52-year-old male who presented to our hospital with cervical lymphadenopathy. Lymph node biopsy revealed small atypical lymphoid cells positive for CD3 and CD5 and negative for CD56 and Epstein-Barr virus (EBV)-encoded small RNA (EBER) by in situ hybridization. CD4-positive cells and CD8-positive cells were mixed in almost equal numbers. He was diagnosed with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). The patient received one cycle of chemotherapy, resulting in severe sepsis. While undergoing treatment in the intensive care unit with an antimicrobial agent and prednisone, ascitic fluid appeared. Abdominal aspiration revealed neutrophil-predominant ascites and microbiological studies revealed Candida albicans. However, ascites did not improve when treated with micafungin for Candida peritonitis. Abdominal aspiration was re-performed, and atypical lymphoid cells that were positive for CD3 and CD56 were detected. EBV-DNA levels in whole blood were significantly elevated. Atypical lymphoid cells were positive for EBER by in situ hybridization and Southern blot analysis showed EBV terminal repeat monoclonal patterns. Bone marrow examination revealed the same atypical lymphoid cells. Therefore, the patient was diagnosed with extranodal natural killer/T-cell lymphoma (ENKTL) with bone marrow involvement 3 months after the diagnosis of PTCL-NOS. Complications associated with PTCL-NOS and ENKTL are rare. PTCL-NOS, chemotherapy, sepsis, and prednisone might have led to immunodeficiency and reactivation of EBV, which might be one of the pathophysiologies for developing ENKTL. Our case indicates that measuring EBV-DNA in the blood is a simple and prompt examination to detect complications of EBV-associated lymphoma.

我们报告了一例因颈部淋巴结病就诊的 52 岁男性病例。淋巴结活检发现,小的非典型淋巴细胞 CD3 和 CD5 阳性,CD56 和爱泼斯坦-巴氏病毒(EBV)编码的小核糖核酸(EBER)原位杂交阴性。CD4 阳性细胞和 CD8 阳性细胞混合在一起,数量几乎相等。他被诊断为外周 T 细胞淋巴瘤,未另作说明(PTCL-NOS)。患者接受了一个周期的化疗,导致严重败血症。在重症监护室接受抗菌剂和泼尼松治疗时,出现了腹水。腹腔抽吸发现腹水以中性粒细胞为主,微生物学检查发现是白色念珠菌。然而,在使用治疗念珠菌腹膜炎的米卡芬净治疗后,腹水并没有改善。再次进行腹腔穿刺,发现了 CD3 和 CD56 阳性的非典型淋巴细胞。全血中的 EBV-DNA 水平明显升高。通过原位杂交,非典型淋巴细胞对 EBER 呈阳性,Southern 印迹分析显示 EBV 末端重复单克隆模式。骨髓检查也发现了同样的非典型淋巴细胞。因此,在确诊PTCL-NOS 3个月后,患者被诊断为骨髓受累的结外自然杀伤/T细胞淋巴瘤(ENKTL)。与PTCL-NOS和ENKTL相关的并发症很少见。PTCL-NOS、化疗、败血症和泼尼松可能导致免疫缺陷和EB病毒再激活,这可能是ENKTL发病的病理生理学原因之一。我们的病例表明,检测血液中的EBV-DNA是发现EBV相关淋巴瘤并发症的一种简单而迅速的检查方法。
{"title":"Extranodal natural killer/T-cell lymphoma coexisting with peripheral T-cell lymphoma, not otherwise specified.","authors":"Kenta Hayashino, Chikamasa Yoshida, Yoshiyuki Ayata, Ryouya Yukawa, Aya Komura, Makoto Nakamura, Yusuke Meguri, Kazuhiko Yamamoto, Wakako Oda, Kenji Imajo","doi":"10.3960/jslrt.23049","DOIUrl":"10.3960/jslrt.23049","url":null,"abstract":"<p><p>We report the case of a 52-year-old male who presented to our hospital with cervical lymphadenopathy. Lymph node biopsy revealed small atypical lymphoid cells positive for CD3 and CD5 and negative for CD56 and Epstein-Barr virus (EBV)-encoded small RNA (EBER) by in situ hybridization. CD4-positive cells and CD8-positive cells were mixed in almost equal numbers. He was diagnosed with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). The patient received one cycle of chemotherapy, resulting in severe sepsis. While undergoing treatment in the intensive care unit with an antimicrobial agent and prednisone, ascitic fluid appeared. Abdominal aspiration revealed neutrophil-predominant ascites and microbiological studies revealed Candida albicans. However, ascites did not improve when treated with micafungin for Candida peritonitis. Abdominal aspiration was re-performed, and atypical lymphoid cells that were positive for CD3 and CD56 were detected. EBV-DNA levels in whole blood were significantly elevated. Atypical lymphoid cells were positive for EBER by in situ hybridization and Southern blot analysis showed EBV terminal repeat monoclonal patterns. Bone marrow examination revealed the same atypical lymphoid cells. Therefore, the patient was diagnosed with extranodal natural killer/T-cell lymphoma (ENKTL) with bone marrow involvement 3 months after the diagnosis of PTCL-NOS. Complications associated with PTCL-NOS and ENKTL are rare. PTCL-NOS, chemotherapy, sepsis, and prednisone might have led to immunodeficiency and reactivation of EBV, which might be one of the pathophysiologies for developing ENKTL. Our case indicates that measuring EBV-DNA in the blood is a simple and prompt examination to detect complications of EBV-associated lymphoma.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 1","pages":"52-58"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11079987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrence of solitary plasmacytoma in the liver 10 years after the onset of multiple bone lesions. 多发性骨病10年后肝脏单发浆细胞瘤复发。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.23056
Jun Numata, Hiroko Tsunemine, Asuka Imai, Naokazu Nakamura, Tomomi Sakai, Tomoo Itoh, Nobuyoshi Arima

A 79-year-old man presented with a history of solitary plasmacytoma in the bone 10 years ago. Chemoradiotherapy was effective, and remission was maintained with intermittent treatment at relapse of the bone lesions. One year after the last treatment, a follow-up computed tomography (CT) scan revealed multiple liver masses, and a liver biopsy revealed plasmacytoma. There was no clonal plasma cell infiltration in the bone marrow, and the final diagnosis was solitary plasmacytomas of the liver. Although liver involvement is known in relapsed refractory multiple myeloma, solitary plasmacytoma in the relapsed stage confined to the liver is rare, and all previous reports have been from the initial presentation. To the best of our knowledge, this is the first recurrent case of solitary plasmacytoma of the liver.

一名 79 岁的男性患者 10 年前曾患单发骨浆细胞瘤。化疗放疗有效,在骨病变复发时进行间歇性治疗,病情得到缓解。最后一次治疗一年后,随访计算机断层扫描(CT)发现肝脏多发肿块,肝脏活检发现浆细胞瘤。骨髓中没有克隆性浆细胞浸润,最终诊断为肝单发浆细胞瘤。虽然已知复发难治性多发性骨髓瘤会累及肝脏,但复发阶段局限于肝脏的单发浆细胞瘤并不多见,而且之前的所有报道都是初次发病时的报道。据我们所知,这是首例复发性肝单发浆细胞瘤病例。
{"title":"Recurrence of solitary plasmacytoma in the liver 10 years after the onset of multiple bone lesions.","authors":"Jun Numata, Hiroko Tsunemine, Asuka Imai, Naokazu Nakamura, Tomomi Sakai, Tomoo Itoh, Nobuyoshi Arima","doi":"10.3960/jslrt.23056","DOIUrl":"10.3960/jslrt.23056","url":null,"abstract":"<p><p>A 79-year-old man presented with a history of solitary plasmacytoma in the bone 10 years ago. Chemoradiotherapy was effective, and remission was maintained with intermittent treatment at relapse of the bone lesions. One year after the last treatment, a follow-up computed tomography (CT) scan revealed multiple liver masses, and a liver biopsy revealed plasmacytoma. There was no clonal plasma cell infiltration in the bone marrow, and the final diagnosis was solitary plasmacytomas of the liver. Although liver involvement is known in relapsed refractory multiple myeloma, solitary plasmacytoma in the relapsed stage confined to the liver is rare, and all previous reports have been from the initial presentation. To the best of our knowledge, this is the first recurrent case of solitary plasmacytoma of the liver.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 1","pages":"65-70"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11079988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extranodal NK/T-cell lymphoma with localized relapse in bone marrow of lower leg detected using PET-CT. PET-CT 发现小腿骨髓局部复发的结节外 NK/T 细胞淋巴瘤。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.23046
Takahisa Nakamura, Hiro Tatetsu, Yusuke Higuchi, Shinya Endo, Shinya Shiraishi, Koichi Kawanaka, Daisuke Imakane, Miyu Sonoda, Rie Furuta, Takafumi Shichijo, Yumi Honda, Kennosuke Karube, Yoshiki Mikami, Kisato Nosaka, Masao Matsuoka, Jun-Ichirou Yasunaga

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma (NHL) with poor prognosis, particularly in relapsed or refractory patients. Thus, timely detection of relapse and appropriate disease management are crucial. We present two patients with ENKTL, wherein positron emission tomography-computed tomography (PET-CT) with total-body coverage after induction therapy, detected newly relapsed regions in the bone marrow of the lower leg prior to progression. Case 1: A 47-year-old woman with nasal obstruction, showing 18F-fluoro-deoxyglucose (FDG) uptake in the nasal cavity (Lugano stage IE). After induction therapy (RT-2/3 DeVIC), PET-CT revealed abnormal uptake only in the right fibula. Case 2: A 68-year-old man with a skin nodule/ulcer and an enlarged right inguinal lymph node was diagnosed with advanced ENKTL. A PET-CT scan revealed abnormal uptake in the subcutaneous mass of the right medial thigh, lymph nodes, and descending colon (Lugano stage IV). After induction therapy, PET-CT revealed new abnormal uptake only in the left tibia. In both patients, CT-guided biopsy confirmed ENKTL recurrence. Moreover, PET-CT with whole-body coverage was useful for the timely assessment of relapse and detection of asymptomatic bone involvement. This approach allowed for modifications to treatment strategies in certain patients.

结节外天然杀伤(NK)/T细胞淋巴瘤(ENKTL)是非霍奇金淋巴瘤(NHL)的一种罕见亚型,预后较差,尤其是复发或难治性患者。因此,及时发现复发并进行适当的疾病治疗至关重要。我们介绍了两名ENKTL患者,他们在接受诱导治疗后,全身覆盖的正电子发射计算机断层扫描(PET-CT)在病情进展前发现了小腿骨髓中新复发的区域。病例 1:47 岁女性,鼻塞,鼻腔显示 18F- 氟脱氧葡萄糖(FDG)摄取(卢加诺 IE 期)。经过诱导治疗(RT-2/3 DeVIC)后,PET-CT 显示只有右腓骨有异常摄取。病例 2:一名 68 岁的男性,患有皮肤结节/溃疡和右腹股沟淋巴结肿大,被诊断为晚期 ENKTL。PET-CT 扫描显示右大腿内侧皮下肿块、淋巴结和降结肠摄取异常(卢加诺 IV 期)。诱导治疗后,PET-CT 发现仅左侧胫骨有新的异常摄取。在这两名患者中,CT 引导活检证实 ENKTL 复发。此外,覆盖全身的 PET-CT 对于及时评估复发和检测无症状骨受累非常有用。这种方法有助于对某些患者的治疗策略进行调整。
{"title":"Extranodal NK/T-cell lymphoma with localized relapse in bone marrow of lower leg detected using PET-CT.","authors":"Takahisa Nakamura, Hiro Tatetsu, Yusuke Higuchi, Shinya Endo, Shinya Shiraishi, Koichi Kawanaka, Daisuke Imakane, Miyu Sonoda, Rie Furuta, Takafumi Shichijo, Yumi Honda, Kennosuke Karube, Yoshiki Mikami, Kisato Nosaka, Masao Matsuoka, Jun-Ichirou Yasunaga","doi":"10.3960/jslrt.23046","DOIUrl":"10.3960/jslrt.23046","url":null,"abstract":"<p><p>Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma (NHL) with poor prognosis, particularly in relapsed or refractory patients. Thus, timely detection of relapse and appropriate disease management are crucial. We present two patients with ENKTL, wherein positron emission tomography-computed tomography (PET-CT) with total-body coverage after induction therapy, detected newly relapsed regions in the bone marrow of the lower leg prior to progression. Case 1: A 47-year-old woman with nasal obstruction, showing 18F-fluoro-deoxyglucose (FDG) uptake in the nasal cavity (Lugano stage IE). After induction therapy (RT-2/3 DeVIC), PET-CT revealed abnormal uptake only in the right fibula. Case 2: A 68-year-old man with a skin nodule/ulcer and an enlarged right inguinal lymph node was diagnosed with advanced ENKTL. A PET-CT scan revealed abnormal uptake in the subcutaneous mass of the right medial thigh, lymph nodes, and descending colon (Lugano stage IV). After induction therapy, PET-CT revealed new abnormal uptake only in the left tibia. In both patients, CT-guided biopsy confirmed ENKTL recurrence. Moreover, PET-CT with whole-body coverage was useful for the timely assessment of relapse and detection of asymptomatic bone involvement. This approach allowed for modifications to treatment strategies in certain patients.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 1","pages":"45-51"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11079990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A lymph node lesion of hyper IL-6 syndrome mimicking plasmacytoma, IgG4-related disease, and Castleman disease. 高IL-6综合征的淋巴结病变,类似浆细胞瘤、igg4相关疾病和Castleman病。
IF 0.9 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24039
Kenta Matsui, Hiroshi Imai, Toshiaki Kobayashi, Minoru Mizutani, Midori Filiz Nishimura, Yasuharu Sato, Kennosuke Karube, Manato Okada, Miki Usui, Keiki Kawakami, Tetsuya Murata

A 72-year-old male patient presented fatigue, anemia, elevated total protein, IgG, IgG4, IL-6, and vascular endothelial growth factor (VEGF) levels. Initial diagnostics suspected multiple myeloma. A plane computed tomography (CT) scan showed pneumonia and the enlargement of generalized lymph nodes. A lymph node biopsy revealed a mix of immature and mature plasma cells, significant IgG4-positive cells, and IL-6-secreting plasma cells, mimicking plasmacytoma, IgG4-related disease, and Castleman disease, ultimately leading to a diagnosis of hyper IL-6 syndrome. Treatment with antibiotics improved the patient's condition without the need for additional therapies, including tocilizumab.

72岁男性患者表现为疲劳、贫血、总蛋白、IgG、IgG4、IL-6和血管内皮生长因子(VEGF)水平升高。初步诊断怀疑多发性骨髓瘤。平面计算机断层扫描显示肺炎和广泛性淋巴结肿大。淋巴结活检显示未成熟和成熟浆细胞、显著的igg4阳性细胞和分泌IL-6的浆细胞混合,模拟浆细胞瘤、igg4相关疾病和Castleman病,最终导致高IL-6综合征的诊断。抗生素治疗改善了患者的病情,而不需要额外的治疗,包括托珠单抗。
{"title":"A lymph node lesion of hyper IL-6 syndrome mimicking plasmacytoma, IgG4-related disease, and Castleman disease.","authors":"Kenta Matsui, Hiroshi Imai, Toshiaki Kobayashi, Minoru Mizutani, Midori Filiz Nishimura, Yasuharu Sato, Kennosuke Karube, Manato Okada, Miki Usui, Keiki Kawakami, Tetsuya Murata","doi":"10.3960/jslrt.24039","DOIUrl":"10.3960/jslrt.24039","url":null,"abstract":"<p><p>A 72-year-old male patient presented fatigue, anemia, elevated total protein, IgG, IgG4, IL-6, and vascular endothelial growth factor (VEGF) levels. Initial diagnostics suspected multiple myeloma. A plane computed tomography (CT) scan showed pneumonia and the enlargement of generalized lymph nodes. A lymph node biopsy revealed a mix of immature and mature plasma cells, significant IgG4-positive cells, and IL-6-secreting plasma cells, mimicking plasmacytoma, IgG4-related disease, and Castleman disease, ultimately leading to a diagnosis of hyper IL-6 syndrome. Treatment with antibiotics improved the patient's condition without the need for additional therapies, including tocilizumab.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 4","pages":"307-312"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD30- and CD56-positive atypical intravascular lymphocytes of the uterine cervix, mimicking intravascular lymphoma: A case report and review of the literature. CD30和cd56阳性的宫颈非典型血管内淋巴细胞,模拟血管内淋巴瘤:1例报告和文献复习。
IF 0.9 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24058
Daisuke Yamashita, Munemichi Otani, Hayato Maruoka, Takuya Aoki, Shigeo Hara

Intravascular accumulation of atypical large lymphoid cells is a rare condition that necessitates a differential diagnosis of intravascular lymphoma (IVL). Recently, a non-neoplastic condition known as benign atypical intravascular CD30+ T-cell proliferation (BAITP) has been identified. This condition is characterized by CD30+ and CD3+ or CD4+ atypical T-cells and is often associated with trauma and chronic inflammation. This case highlights atypical intravascular lymphoid cells of the uterine cervix that are positive for CD30 and CD56 and can mimic IVL.

非典型大淋巴细胞血管内积聚是一种罕见的情况,需要鉴别诊断血管内淋巴瘤(IVL)。最近,一种被称为良性非典型血管内CD30+ t细胞增殖(BAITP)的非肿瘤性疾病被发现。这种疾病的特征是CD30+和CD3+或CD4+非典型t细胞,通常与创伤和慢性炎症有关。本病例突出显示子宫颈非典型血管内淋巴样细胞CD30和CD56阳性,可模拟IVL。
{"title":"CD30- and CD56-positive atypical intravascular lymphocytes of the uterine cervix, mimicking intravascular lymphoma: A case report and review of the literature.","authors":"Daisuke Yamashita, Munemichi Otani, Hayato Maruoka, Takuya Aoki, Shigeo Hara","doi":"10.3960/jslrt.24058","DOIUrl":"10.3960/jslrt.24058","url":null,"abstract":"<p><p>Intravascular accumulation of atypical large lymphoid cells is a rare condition that necessitates a differential diagnosis of intravascular lymphoma (IVL). Recently, a non-neoplastic condition known as benign atypical intravascular CD30+ T-cell proliferation (BAITP) has been identified. This condition is characterized by CD30+ and CD3+ or CD4+ atypical T-cells and is often associated with trauma and chronic inflammation. This case highlights atypical intravascular lymphoid cells of the uterine cervix that are positive for CD30 and CD56 and can mimic IVL.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 4","pages":"328-331"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epstein-Barr virus-positive plasmacytoma in an immunocompetent female: A case report. 一名免疫功能正常女性的 Epstein-Barr 病毒阳性浆细胞瘤:病例报告。
IF 0.9 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24038
Hiyo Okuno, Motoha Miura, Naoki Oishi, Megumi Koshiishi-Yamada, Fumihiko Tanioka, Keita Kirito, Tetsuo Kondo

Plasmacytoma is defined as a plasma cell neoplasm forming a solitary osseous or extramedullary tumor without evidence of myeloma or organ damage related to a plasma cell neoplasm. Epstein-Barr virus (EBV) is associated with various B-cell neoplasms, particularly in patients with immune dysregulation; however, plasmacytoma is typically negative for EBV. Here, a case of EBV-positive sternal plasmacytoma in an immunocompetent female is presented. A 76-year-old female with no immunodeficiency presented with a tumor on the anterior thoracic wall. Imaging analysis revealed a 6.3 cm-sized tumor at the manubrium, and a needle biopsy was performed. The tumor in the bone was composed of a diffuse proliferation of plasmacytes with eccentric nuclei and a perinuclear halo. By immunohistochemistry and in situ hybridization, tumor cells were CD20-, CD3-, CD138+, κ+, λ-, EBER+, and the Ki67-labeling index was approximately 20%. Subsequent studies identified IgG κ monoclonal protein in serum but no evidence of plasma cell neoplasm-related organ damage, such as hypercalcemia, anemia, or renal dysfunction. No plasma cell neoplasm was detected in the bone marrow in the morphological and flowcytometric studies. Accordingly, the diagnosis was EBV-positive plasmacytoma. The patient was treated with local radiation therapy and achieved complete remission. EBV-positive plasmacytoma is rare in immunocompetent patients and should be carefully distinguished from plasmablastic lymphoma, another EBV-positive neoplasm with a plasma cell phenotype and an aggressive clinical course. This case also raises an important question: "when to perform EBER in situ hybridization in diagnosing plasma cell neoplasm?", which prompts further large case-series studies.

浆细胞瘤的定义是形成单发骨性或髓外肿瘤的浆细胞肿瘤,没有骨髓瘤或浆细胞肿瘤相关器官损伤的证据。爱泼斯坦-巴氏病毒(EBV)与各种B细胞肿瘤有关,尤其是在免疫失调的患者中;然而,浆细胞瘤通常对EBV呈阴性反应。本文介绍了一例免疫功能正常女性胸骨浆细胞瘤 EBV 阳性病例。一名 76 岁女性,无免疫缺陷,胸前壁出现肿瘤。影像学分析显示,鬃骨处有一个 6.3 厘米大小的肿瘤,于是进行了针刺活检。骨中的肿瘤由弥漫增生的浆细胞组成,具有偏心核和核周晕。通过免疫组化和原位杂交,肿瘤细胞为 CD20-、CD3-、CD138+、κ+、λ-、EBER+,Ki67 标记指数约为 20%。随后的研究发现血清中存在IgG κ单克隆蛋白,但没有证据表明存在浆细胞肿瘤相关的器官损伤,如高钙血症、贫血或肾功能障碍。在骨髓形态学和流式细胞术研究中未发现浆细胞肿瘤。因此,诊断结果为 EBV 阳性浆细胞瘤。患者接受了局部放射治疗,病情完全缓解。EBV阳性浆细胞瘤在免疫功能正常的患者中非常罕见,应与浆细胞性淋巴瘤仔细鉴别,后者是另一种EBV阳性肿瘤,具有浆细胞表型和侵袭性临床病程。这个病例也提出了一个重要问题:"在诊断浆细胞肿瘤时何时进行 EBER 原位杂交?
{"title":"Epstein-Barr virus-positive plasmacytoma in an immunocompetent female: A case report.","authors":"Hiyo Okuno, Motoha Miura, Naoki Oishi, Megumi Koshiishi-Yamada, Fumihiko Tanioka, Keita Kirito, Tetsuo Kondo","doi":"10.3960/jslrt.24038","DOIUrl":"10.3960/jslrt.24038","url":null,"abstract":"<p><p>Plasmacytoma is defined as a plasma cell neoplasm forming a solitary osseous or extramedullary tumor without evidence of myeloma or organ damage related to a plasma cell neoplasm. Epstein-Barr virus (EBV) is associated with various B-cell neoplasms, particularly in patients with immune dysregulation; however, plasmacytoma is typically negative for EBV. Here, a case of EBV-positive sternal plasmacytoma in an immunocompetent female is presented. A 76-year-old female with no immunodeficiency presented with a tumor on the anterior thoracic wall. Imaging analysis revealed a 6.3 cm-sized tumor at the manubrium, and a needle biopsy was performed. The tumor in the bone was composed of a diffuse proliferation of plasmacytes with eccentric nuclei and a perinuclear halo. By immunohistochemistry and in situ hybridization, tumor cells were CD20-, CD3-, CD138+, κ+, λ-, EBER+, and the Ki67-labeling index was approximately 20%. Subsequent studies identified IgG κ monoclonal protein in serum but no evidence of plasma cell neoplasm-related organ damage, such as hypercalcemia, anemia, or renal dysfunction. No plasma cell neoplasm was detected in the bone marrow in the morphological and flowcytometric studies. Accordingly, the diagnosis was EBV-positive plasmacytoma. The patient was treated with local radiation therapy and achieved complete remission. EBV-positive plasmacytoma is rare in immunocompetent patients and should be carefully distinguished from plasmablastic lymphoma, another EBV-positive neoplasm with a plasma cell phenotype and an aggressive clinical course. This case also raises an important question: \"when to perform EBER in situ hybridization in diagnosing plasma cell neoplasm?\", which prompts further large case-series studies.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 3","pages":"268-272"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticancer immune reaction and lymph node sinus macrophages: a review from human and animal studies. 抗癌免疫反应和淋巴结窦巨噬细胞:人类和动物研究综述。
IF 0.9 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24017
Yukio Fujiwara, Hiromu Yano, Cheng Pan, Takuya Shiota, Yoshihiro Komohara

Lymph nodes are secondary lymphoid organs localized throughout the body that typically appear as bean-like nodules. Numerous antigen-presenting cells, including dendritic cells and macrophages, that mediate host defense responses against pathogens, such as bacteria and viruses, reside within lymph nodes. To react to cancer cell-derived antigens in a variety of cancers, antigen-presenting cells induce cytotoxic T lymphocytes (CTLs). In relation to anticancer immune responses, macrophages in the lymph node sinus have been of particular interest because a number of studies involving both human specimens and animal models have reported that lymph node macrophages expressing CD169 play a key role in activating anticancer CTLs. Recent studies have indicated that dysfunction of lymph node macrophages potentially contributes to immune suppression in elderly patients and immunological "cold" tumors. Therefore, in anticancer therapy, the regulation of lymph node macrophages is a potentially promising approach.

淋巴结是遍布全身的次级淋巴器官,通常呈豆状结节。淋巴结内有许多抗原递呈细胞,包括树突状细胞和巨噬细胞,它们能介导宿主对细菌和病毒等病原体的防御反应。为了对各种癌症的癌细胞衍生抗原做出反应,抗原递呈细胞会诱导细胞毒性 T 淋巴细胞(CTL)。关于抗癌免疫反应,淋巴结窦中的巨噬细胞尤其引人关注,因为许多涉及人体标本和动物模型的研究报告称,表达 CD169 的淋巴结巨噬细胞在激活抗癌 CTL 方面发挥着关键作用。最近的研究表明,淋巴结巨噬细胞的功能障碍可能会导致老年患者和免疫学 "冷 "肿瘤的免疫抑制。因此,在抗癌治疗中,调节淋巴结巨噬细胞是一种具有潜在前景的方法。
{"title":"Anticancer immune reaction and lymph node sinus macrophages: a review from human and animal studies.","authors":"Yukio Fujiwara, Hiromu Yano, Cheng Pan, Takuya Shiota, Yoshihiro Komohara","doi":"10.3960/jslrt.24017","DOIUrl":"10.3960/jslrt.24017","url":null,"abstract":"<p><p>Lymph nodes are secondary lymphoid organs localized throughout the body that typically appear as bean-like nodules. Numerous antigen-presenting cells, including dendritic cells and macrophages, that mediate host defense responses against pathogens, such as bacteria and viruses, reside within lymph nodes. To react to cancer cell-derived antigens in a variety of cancers, antigen-presenting cells induce cytotoxic T lymphocytes (CTLs). In relation to anticancer immune responses, macrophages in the lymph node sinus have been of particular interest because a number of studies involving both human specimens and animal models have reported that lymph node macrophages expressing CD169 play a key role in activating anticancer CTLs. Recent studies have indicated that dysfunction of lymph node macrophages potentially contributes to immune suppression in elderly patients and immunological \"cold\" tumors. Therefore, in anticancer therapy, the regulation of lymph node macrophages is a potentially promising approach.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 2","pages":"71-78"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical lymphoplasmacytic and immunoblastic proliferation: A Systematic Review. 非典型淋巴浆细胞和免疫母细胞增生:系统综述。
IF 0.9 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24007
Midori Filiz Nishimura, Toshiaki Takahashi, Kensuke Takaoka, Sharina Macapagal, Chalothorn Wannaphut, Asami Nishikori, Hiroko Toda, Yoshito Nishimura, Yasuharu Sato

Atypical lymphoplasmacytic and immunoblastic proliferation (ALPIBP) was first reported in 1984 as characteristic histological findings in lymph nodes associated with autoimmune diseases, but it has not been clearly defined to date. To summarize the histological characteristics and clinical diagnoses associated with ALPIBP, we searched MEDLINE and EMBASE for all peer-reviewed articles using keywords including "atypical lymphoplasmacytic and immunoblastic lymphadenopathy" from their inception to December 27, 2023. We also summarized the courses of three cases with a pathological diagnosis of ALPIBP. Nine articles with 52 cases were included. Among the total of 55 cases, including the three from our institution, the median age of the cases was 63.5 years with a female predominance (69.5%). Lymphadenopathy was generalized in 65.6% and regional in 34.4% of cases. RA (24.4%), SLE (24.4%), and autoimmune hemolytic anemia (20.0%), were common clinical diagnoses. A combination of cytotoxic chemotherapy was used in 15.6% of cases due to the suspicion of malignancy. Nodal T-follicular helper cell lymphoma, angioimmunoblastic type, methotrexate-associated lymphoproliferative disorders, and IgG4-related diseases were listed as important diseases that need to be pathologically differentiated from ALPIBP. This review summarizes the current understanding of the characteristics of ALPIBP. Given that underrecognition of ALPIBP could lead to overdiagnosis of hematological malignancy and unnecessary treatment, increased awareness of the condition in pathologists and clinicians is crucial.

非典型淋巴浆细胞和免疫母细胞增生(ALPIBP)作为与自身免疫性疾病相关的淋巴结的特征性组织学发现于1984年首次被报道,但迄今为止还没有明确的定义。为了总结与 ALPIBP 相关的组织学特征和临床诊断,我们检索了自 MEDLINE 和 EMBASE 开始至 2023 年 12 月 27 日的所有同行评审文章,关键词包括 "非典型淋巴浆细胞性和免疫母细胞性淋巴结病"。我们还总结了病理诊断为 ALPIBP 的三个病例的病程。共纳入 9 篇文章,52 个病例。在总共 55 例病例中,包括本院的 3 例病例,病例的中位年龄为 63.5 岁,女性占多数(69.5%)。65.6%的病例为全身性淋巴结病,34.4%为区域性淋巴结病。RA(24.4%)、系统性红斑狼疮(24.4%)和自身免疫性溶血性贫血(20.0%)是常见的临床诊断。15.6%的病例因怀疑恶性肿瘤而采用了联合细胞毒化疗。结节性T滤泡辅助细胞淋巴瘤、血管免疫母细胞型、甲氨蝶呤相关淋巴增生性疾病和IgG4相关疾病被列为需要与ALPIBP进行病理鉴别的重要疾病。本综述总结了目前对 ALPIBP 特征的认识。鉴于对 ALPIBP 的认识不足可能会导致血液恶性肿瘤的过度诊断和不必要的治疗,因此提高病理学家和临床医生对这种疾病的认识至关重要。
{"title":"Atypical lymphoplasmacytic and immunoblastic proliferation: A Systematic Review.","authors":"Midori Filiz Nishimura, Toshiaki Takahashi, Kensuke Takaoka, Sharina Macapagal, Chalothorn Wannaphut, Asami Nishikori, Hiroko Toda, Yoshito Nishimura, Yasuharu Sato","doi":"10.3960/jslrt.24007","DOIUrl":"10.3960/jslrt.24007","url":null,"abstract":"<p><p>Atypical lymphoplasmacytic and immunoblastic proliferation (ALPIBP) was first reported in 1984 as characteristic histological findings in lymph nodes associated with autoimmune diseases, but it has not been clearly defined to date. To summarize the histological characteristics and clinical diagnoses associated with ALPIBP, we searched MEDLINE and EMBASE for all peer-reviewed articles using keywords including \"atypical lymphoplasmacytic and immunoblastic lymphadenopathy\" from their inception to December 27, 2023. We also summarized the courses of three cases with a pathological diagnosis of ALPIBP. Nine articles with 52 cases were included. Among the total of 55 cases, including the three from our institution, the median age of the cases was 63.5 years with a female predominance (69.5%). Lymphadenopathy was generalized in 65.6% and regional in 34.4% of cases. RA (24.4%), SLE (24.4%), and autoimmune hemolytic anemia (20.0%), were common clinical diagnoses. A combination of cytotoxic chemotherapy was used in 15.6% of cases due to the suspicion of malignancy. Nodal T-follicular helper cell lymphoma, angioimmunoblastic type, methotrexate-associated lymphoproliferative disorders, and IgG4-related diseases were listed as important diseases that need to be pathologically differentiated from ALPIBP. This review summarizes the current understanding of the characteristics of ALPIBP. Given that underrecognition of ALPIBP could lead to overdiagnosis of hematological malignancy and unnecessary treatment, increased awareness of the condition in pathologists and clinicians is crucial.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 2","pages":"97-106"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma. 通过传统细胞遗传学分析确定的复杂核型是多发性骨髓瘤患者预后不良的一个因素。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.23047
Hideki Uryu, Yuko Mishima, Yuko Ishihara, Yuko Shirouchi, Nobuhiko Yamauchi, Mitsuhito Hirano, Kei Hirano, Yukako Teramoto, Kikuaki Yoshida, Dai Maruyama

High-risk cytogenetic abnormalities (HRCAs) influence the prognosis of multiple myeloma (MM). However, additional cytogenetic aberrations can lead to poor outcomes. This study aimed to clarify whether HRCAs and additional chromosomal abnormalities affect MM prognosis. Patients with newly diagnosed MM who were treated with novel agents were retrospectively evaluated. The primary objective was to assess the difference in progression-free survival (PFS) and overall survival (OS) between patients with/without HRCAs and between patients with/without complex karyotype (CK). The secondary objectives were to identify factors affecting PFS/OS and factors related to CK. HRCAs were defined as del(17p), t(4;14), t(14;16), and gain/amplification(1q) assessed using fluorescence in situ hybridization. CK was defined as ≥3 chromosomal abnormalities on G-banding. Among 110 patients, 40 had HRCAs and 15 had CK. In this study, survival durations between patients with/without HRCAs were similar, while the CK group had significantly poorer PFS/OS than the no-CK group (median PFS: 9 vs. 24 months and median OS: 29 vs. 97 months, respectively), and a poor prognostic impact of CK was maintained in patients with HRCAs. In multivariate analysis, CK was correlated with poor PFS/OS (hazard ratio [HR]: 2.39, 95% confidence interval [95% CI]: 1.22-4.66 and HR: 2.66, 95% CI: 1.10-6.45, respectively). Bone marrow plasma cell (BMPC) ≥60% (odds ratio [OR] = 6.40, 95% CI: 1.50-27.2) and Revised International Staging System III (OR = 7.53, 95% CI: 2.09-27.1) were associated with CK. Our study suggests that CK may contribute to the poor prognosis of MM. Aggressive disease status including high BMPC proliferation could be relevant to CK.

高危细胞遗传学异常(HRCAs)会影响多发性骨髓瘤(MM)的预后。然而,其他细胞遗传学畸变也会导致不良预后。本研究旨在明确高危细胞遗传学异常和其他染色体异常是否会影响多发性骨髓瘤的预后。研究人员对接受新型药物治疗的新诊断MM患者进行了回顾性评估。首要目标是评估有/无 HRCAs 患者之间以及有/无复杂核型(CK)患者之间的无进展生存期(PFS)和总生存期(OS)差异。次要目标是确定影响PFS/OS的因素以及与CK相关的因素。通过荧光原位杂交评估,HRCA的定义为del(17p)、t(4;14)、t(14;16)和增益/扩增(1q)。CK的定义是G带染色体异常≥3条。在110名患者中,40人患有HRCA,15人患有CK。在这项研究中,有/无 HRCAs 患者的生存期相似,而 CK 组的 PFS/OS 明显差于无 CK 组(中位 PFS:分别为 9 个月和 24 个月,中位 OS:分别为 29 个月和 97 个月),CK 对 HRCAs 患者的预后仍有不良影响。在多变量分析中,CK 与较差的 PFS/OS 相关(危险比 [HR]:2.39,95% 置信区间 [95% CI]:1.22-4.66,HR:1.22-4.66):分别为 1.22-4.66 和 HR:2.66,95% 置信区间:1.10-6.45)。骨髓浆细胞(BMPC)≥60%(比值比 [OR] = 6.40,95% CI:1.50-27.2)和修订版国际分期系统 III(OR = 7.53,95% CI:2.09-27.1)与 CK 相关。我们的研究表明,CK可能是导致MM预后不良的原因之一。包括BMPC高增殖在内的侵袭性疾病状态可能与CK有关。
{"title":"Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.","authors":"Hideki Uryu, Yuko Mishima, Yuko Ishihara, Yuko Shirouchi, Nobuhiko Yamauchi, Mitsuhito Hirano, Kei Hirano, Yukako Teramoto, Kikuaki Yoshida, Dai Maruyama","doi":"10.3960/jslrt.23047","DOIUrl":"10.3960/jslrt.23047","url":null,"abstract":"<p><p>High-risk cytogenetic abnormalities (HRCAs) influence the prognosis of multiple myeloma (MM). However, additional cytogenetic aberrations can lead to poor outcomes. This study aimed to clarify whether HRCAs and additional chromosomal abnormalities affect MM prognosis. Patients with newly diagnosed MM who were treated with novel agents were retrospectively evaluated. The primary objective was to assess the difference in progression-free survival (PFS) and overall survival (OS) between patients with/without HRCAs and between patients with/without complex karyotype (CK). The secondary objectives were to identify factors affecting PFS/OS and factors related to CK. HRCAs were defined as del(17p), t(4;14), t(14;16), and gain/amplification(1q) assessed using fluorescence in situ hybridization. CK was defined as ≥3 chromosomal abnormalities on G-banding. Among 110 patients, 40 had HRCAs and 15 had CK. In this study, survival durations between patients with/without HRCAs were similar, while the CK group had significantly poorer PFS/OS than the no-CK group (median PFS: 9 vs. 24 months and median OS: 29 vs. 97 months, respectively), and a poor prognostic impact of CK was maintained in patients with HRCAs. In multivariate analysis, CK was correlated with poor PFS/OS (hazard ratio [HR]: 2.39, 95% confidence interval [95% CI]: 1.22-4.66 and HR: 2.66, 95% CI: 1.10-6.45, respectively). Bone marrow plasma cell (BMPC) ≥60% (odds ratio [OR] = 6.40, 95% CI: 1.50-27.2) and Revised International Staging System III (OR = 7.53, 95% CI: 2.09-27.1) were associated with CK. Our study suggests that CK may contribute to the poor prognosis of MM. Aggressive disease status including high BMPC proliferation could be relevant to CK.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 1","pages":"10-20"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11079984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histiocytic neoplasms: a brief review and differential diagnosis. 组织细胞肿瘤:简要回顾与鉴别诊断。
IF 0.9 Q4 HEMATOLOGY Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24031
Rin Yamada, Yoshihiro Komohara

Histiocytic neoplasms (HNs) include juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman disease, ALK-positive histiocytosis, and histiocytic sarcoma in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours. These entities are clinicopathologically distinctive, and typical histological findings have been established. However, the common feature of a proliferation of histiocytic cells often leads to morphological overlap among HNs, and also necessitates a differential diagnosis from several non-HNs or non-neoplastic conditions. In this review, we provide a brief summary of the clinical findings, molecular features, histopathologies, and immunophenotypes of HNs, as well as to discuss their differential diagnosis.

组织细胞瘤(HNs)包括幼年黄原细胞瘤、埃尔德海姆-切斯特病、罗赛-多夫曼病、ALK 阳性组织细胞增生症,以及世界卫生组织第五版血液淋巴肿瘤分类中的组织细胞肉瘤。这些实体在临床病理上各具特色,典型的组织学检查结果也已确立。然而,组织细胞增生这一共同特征往往会导致 HNs 在形态学上的重叠,而且还需要与几种非 HNs 或非肿瘤性疾病进行鉴别诊断。在本综述中,我们将简要概述 HNs 的临床发现、分子特征、组织病理学和免疫分型,并讨论其鉴别诊断。
{"title":"Histiocytic neoplasms: a brief review and differential diagnosis.","authors":"Rin Yamada, Yoshihiro Komohara","doi":"10.3960/jslrt.24031","DOIUrl":"10.3960/jslrt.24031","url":null,"abstract":"<p><p>Histiocytic neoplasms (HNs) include juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman disease, ALK-positive histiocytosis, and histiocytic sarcoma in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours. These entities are clinicopathologically distinctive, and typical histological findings have been established. However, the common feature of a proliferation of histiocytic cells often leads to morphological overlap among HNs, and also necessitates a differential diagnosis from several non-HNs or non-neoplastic conditions. In this review, we provide a brief summary of the clinical findings, molecular features, histopathologies, and immunophenotypes of HNs, as well as to discuss their differential diagnosis.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 3","pages":"156-165"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical and Experimental Hematopathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1